[go: up one dir, main page]

EP0572627A1 - Systeme de solvant destine a etre enferme dans des capsules. - Google Patents

Systeme de solvant destine a etre enferme dans des capsules.

Info

Publication number
EP0572627A1
EP0572627A1 EP93901341A EP93901341A EP0572627A1 EP 0572627 A1 EP0572627 A1 EP 0572627A1 EP 93901341 A EP93901341 A EP 93901341A EP 93901341 A EP93901341 A EP 93901341A EP 0572627 A1 EP0572627 A1 EP 0572627A1
Authority
EP
European Patent Office
Prior art keywords
solvent system
weight
mole
capsules
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP93901341A
Other languages
German (de)
English (en)
Other versions
EP0572627B1 (fr
Inventor
Hirokazu Makino
Ichiro Hakamada
Osamu Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalent Pharma Solutions Inc
Original Assignee
Catalent Pharma Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Pharma Solutions Inc filed Critical Catalent Pharma Solutions Inc
Publication of EP0572627A1 publication Critical patent/EP0572627A1/fr
Application granted granted Critical
Publication of EP0572627B1 publication Critical patent/EP0572627B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • this solvent system using PEG can cause a local reaction due to existing hydroxide ions depending on the properties of other components in the capsule. As the result, an ester may be produced and, thereby, may cause the purity of the encapsulated contents to be lowered.
  • the inventors of the present invention have earnestly investigated the purity deterioration of the solute component (medicine) due to its reaction with the solvent and found that polyoxyethylene sorbitan fatty acid ester (hereaf er, abbreviated POSE) is a solvent useful for preventing the deterioration of purity, and have reached the present invention.
  • POSE polyoxyethylene sorbitan fatty acid ester
  • the present invention relates to a solvent system that includes a highly concentrated acidic medicine, the solubility of which is enhanced by partial ionization of said medicine.
  • This solvent system is used by being enclosed in soft gels (soft elastic gelatin capsules) or hard gelatin shells.
  • the present invention relates to a high concentration solvent system to be enclosed in capsules, said system being composed of a) 10-80% by weight acidic medicine, b) 0.1-1.0 mole hydroxide ions for one mole of said medicine, and c) 1-20% by weight water included in POSE, the mean molecular weight of said POSE being 600-3000.
  • Ibuprof en Naproxen, Indomethacin, Acetaminophen, etc. may be exemplified as among the acidic medicines to be used in this invention.
  • Said acidic medicine is selectively used in the range of about 10- 80% by weight for the amount of POSE in consideration of the kind of acidic medicine used.
  • the use of the medicine in the region under or over said range is less advantageous because the system may become too low in concentration in the former while it may become inhomogeneous, causing the crystallization of the acidic medicine in the form of insoluble substances in the latter.
  • about 0.1-1.0 mole hydroxide ions is used for each molar equivalent of said acidic medicine.
  • Use of hydroxide ions in the concentration under or over the above-mentioned range is less advantageous because the acidic medicine may not be dissolved in the former, causing an inhomogeneous phase system and, on the other hand, the gelatin constituting the shell of capsules tends to be hydrolyzed in the latter, causing leaking capsules.
  • c) in the present invention about 1-20% by weight water is included in POSE. If the water content is lower than about 1% by weight, the ionization of the acidic medicine might be incomplete though it depends on the nature of the medicine used, making the desired solubility unattainable. On the other hand, if the water content is more than about 20% by weight, the capsule containing such water may be softened and impractical.
  • this water can be added directly to the POSE or the acidic medicine; otherwise it can be added to the hydroxide to be used in order to obtain an aqueous solution of alkaline hydroxide, which is afterwards added to the POSE.
  • POSEs with mean molecular weights of approximately 600-3000 are preferably used.
  • POSEs are well known, for example, under the trade name of Tween (Atlas Powder Co.) and are easily available in the market.
  • Specific POSEs useful in the present invention include:
  • TWEEN 20 ethylene oxide condensate of sorbitanmonolaurate TWEEN 21 ethylene oxide condensate of sorbitanmonolaurate TWEEN 40 ethylene oxide condensate of sorbitanmonopalmitate TWEEN 60 ethylene oxide condensate of sorbitanmonostearate TWEEN 61 ethylene oxide condensate of sorbitanmonostearate
  • TWEEN 65 ethylene oxide condensate of sorbitantristearate TWEEN 80 ethylene oxide condensate of sorbitanmonooleate TWEEN 81 ethylene oxide condensate of sorbitanmonooleate TWEEN 85 ethylene oxide condensate of sorbitantrioleate
  • a) The solubility of acidic medicine can be increased by about 4-
  • Ibuprofen in various polyoxyethylene sorbitan fatty acid ester solutions was partially neutralized with an alkaline solution and preserved 105°C or 44 hours.
  • the amount of ester produced between the acidic formula and the solvent and the content of the remaining Ibuprofen were measured an compared with those in the case where PEG is used instead of POSE.
  • Naproxen in various polyoxyethylene sorbitan fatty acid ester solutio was partially neutralized with an alkaline solution and preserved at 105°C f 44 hours.
  • the amount of ester produced between the acidic medicine and t solvent and the content of the remaining Naproxen were measured to compared with those in the case where PEG is used.
  • Ibuprofen dissolved separate in three kinds of solvents - - two kinds polyoxyethylene sorbitan fatty acid ester (TWEEN 20 and TWEEN 80) an polyethylene glycol - - was partially neutralized (0.3-0.4 m/e) with alkali solutions and the obtained solutions were encapsulated into soft capsules whos shell films are made of 100 parts gelatin, 35 parts glycerin and 15 parts sorbit using a rotary soft-capsule filling machine, producing each capsule whose fi weight is approximately 390mg.
  • solvents - - two kinds polyoxyethylene sorbitan fatty acid ester TWEEN 20 and TWEEN 80
  • an polyethylene glycol - - was partially neutralized (0.3-0.4 m/e) with alkali solutions and the obtained solutions were encapsulated into soft capsules whos shell films are made of 100 parts gelatin, 35 parts glycerin and 15 parts sorbit using a rotary soft-capsule filling machine, producing each capsule whose fi weight is

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pour accroître la solubilité de médicaments acides on prépare un système de solvant très concentré destiné à être encapsulé qui comprend a) de 10 à 80 % en poids de médicament acide, b) de 0,1 à 1,0 mole d'ions hydroxyde par équivalent mole dudit médicament, et c) de 1 à 20 % en poids d'eau. Le solvant est un ester d'acide gras de polyoxyéthylène sorbitan.
EP93901341A 1991-12-19 1992-12-18 Systeme de solvant destine a etre enferme dans des capsules Expired - Lifetime EP0572627B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP337138/91 1991-12-19
JP03337138A JP3121080B2 (ja) 1991-12-19 1991-12-19 カプセル封入用溶液
PCT/US1992/010773 WO1993011753A1 (fr) 1991-12-19 1992-12-18 Systeme de solvant destine a etre enferme dans des capsules

Publications (2)

Publication Number Publication Date
EP0572627A1 true EP0572627A1 (fr) 1993-12-08
EP0572627B1 EP0572627B1 (fr) 1997-09-03

Family

ID=18305803

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93901341A Expired - Lifetime EP0572627B1 (fr) 1991-12-19 1992-12-18 Systeme de solvant destine a etre enferme dans des capsules

Country Status (9)

Country Link
US (1) US5912011A (fr)
EP (1) EP0572627B1 (fr)
JP (1) JP3121080B2 (fr)
AU (1) AU3278393A (fr)
CA (1) CA2103793C (fr)
DE (1) DE69222031T2 (fr)
ES (1) ES2108255T3 (fr)
WO (1) WO1993011753A1 (fr)
ZA (1) ZA929854B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6197787B1 (en) * 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
ATE300293T1 (de) * 1997-03-03 2005-08-15 Sanofi Aventis Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
CA2377204C (fr) * 1999-06-29 2015-01-20 Pharmaceutical Discovery Corporation Purification et stabilisation de produits pharmaceutiques a base de peptides et de proteines
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
CN100366239C (zh) 2001-07-05 2008-02-06 涌永制药株式会社 软胶囊剂
EP1344523A1 (fr) * 2002-03-11 2003-09-17 Warner-Lambert Company Solution d'ibuprofène pour gèlules
EP1494732B1 (fr) 2002-03-20 2008-01-30 MannKind Corporation Appareil d'inhalation
AU2003261633A1 (en) * 2003-02-12 2004-09-06 R And P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
CN1909891A (zh) * 2004-01-09 2007-02-07 惠氏公司 药用组合物的微乳液
KR20060110353A (ko) * 2004-01-12 2006-10-24 맨카인드 코포레이션 제2형 당뇨병 환자에서 혈청 프로인슐린 농도의 감소 방법
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
PT1740154E (pt) * 2004-03-12 2009-09-11 Biodel Inc Composições de insulina com absorção melhorada
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
EP2314298B1 (fr) 2004-08-23 2015-05-27 MannKind Corporation Microparticules comprenant des sels de diketopiperazine permettant l'administration de médicaments
US20060088590A1 (en) * 2004-10-22 2006-04-27 Banner Pharmacaps, Inc. Non-blooming gelatin and non-gelatin formulations
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
EP1928423B1 (fr) 2005-09-14 2015-12-09 Mannkind Corporation Procédé de composition de médicament s appuyant sur une augmentation de l affinité d agents actifs pour des surfaces de microparticules cristallines
JP2009508951A (ja) * 2005-09-19 2009-03-05 アルベマール・コーポレーシヨン カリウムイブプロフェンの極めて濃厚な注入可能な水溶液、その製造法および使用
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (fr) * 2005-09-29 2007-04-12 Biodel, Inc. Preparations d'insuline a action rapide et prolongee
US7582679B2 (en) * 2006-02-03 2009-09-01 Pharmaceutics International Incorporated Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
US7718609B2 (en) * 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2008005742A2 (fr) * 2006-06-30 2008-01-10 Mcneil-Ppc, Inc. Capsules dures emplies d'un liquide contenant de l'ibuprofène
WO2008124522A2 (fr) * 2007-04-04 2008-10-16 Biodel, Inc. Formulations contenant de l'amyline
WO2009069139A1 (fr) * 2007-11-28 2009-06-04 Alkem Laboratories Ltd. Forme posologique fournissant un remplissage liquide contenant de l'ibuprofène
EP2234644B1 (fr) * 2008-01-04 2013-07-31 Biodel, Inc. Préparations d'insuline pour libération d'insuline en fonction de niveaux de glucose dans les tissus
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3153292A1 (fr) 2008-06-13 2009-12-17 Mannkind Corporation Inhalateur de poudre seche et systeme d'administration de medicament
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
CN103751892B (zh) 2008-06-20 2017-03-01 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
MX337488B (es) 2008-07-21 2016-03-08 Si Group Inc Granulos con alto contenido de ibuprofeno sodico, su preparacion y su uso en preparar formas de dosificacion solidas no efervescentes.
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
MX2011009512A (es) 2009-03-11 2011-11-29 Mannkind Corp Aparato, sistema y metodo para medir la resistencia de un inhalador.
CN102647979B (zh) 2009-06-12 2015-03-04 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
US20150250750A1 (en) * 2012-10-16 2015-09-10 Wockhardt Limited Pharmaceutical compostions of diclofenac or salts thereof
WO2014066856A1 (fr) 2012-10-26 2014-05-01 Mannkind Corporation Compositions et procédés de vaccin antigrippal inhalable
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
WO2015021064A1 (fr) 2013-08-05 2015-02-12 Mannkind Corporation Appareil d'insufflation et procédés
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20180071221A1 (en) * 2015-03-02 2018-03-15 Bionpharma Healthcare Llc Immediate release soluble ibuprofen compositions
CN107951857B (zh) * 2017-11-29 2019-12-24 浙江安宝药业有限公司 布洛芬软胶囊
WO2019224832A1 (fr) 2018-05-25 2019-11-28 Strides Shasun Limited Procédé de préparation de compositions pharmaceutiques entrainant une réduction du volume de remplissage global pour une utilisation avec des formulations gélatineuses molles
GB2595300B (en) * 2020-05-21 2024-03-27 Reckitt Benckiser Health Ltd Novel Formulation
GB2595453B (en) * 2020-05-21 2024-04-03 Reckitt Benckiser Health Ltd Novel Formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3202578A (en) * 1957-09-27 1965-08-24 Elder Paul B Co Polymeric laxative composition and method of using same
US4145440A (en) * 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
DE3437599C2 (de) * 1984-10-13 1987-04-16 Dolorgiet GmbH & Co KG, 5205 St Augustin Ibuprofen enthaltende Weichgelatinekapseln
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
DE3629386A1 (de) * 1986-08-29 1988-03-03 Scherer Gmbh R P Gelatinekapseln und verfahren zu ihrer herstellung
US4927638A (en) * 1986-10-08 1990-05-22 Bristol-Myers Company Etoposide solutions
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
EP0278997A1 (fr) * 1987-02-17 1988-08-24 Siegfried Aktiengesellschaft Capsules rectales d'azapropazone
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
US5665384A (en) * 1990-04-06 1997-09-09 Rhone-Poulenc Rorer S.A. Oily capsules of ketoprofen
US5178877A (en) * 1991-01-04 1993-01-12 Abbott Laboratories Encapsulated renin inhibitor composition
US5175002A (en) * 1991-10-02 1992-12-29 Du Pont Merck Pharmaceutical Company Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5376688A (en) * 1992-12-18 1994-12-27 R. P. Scherer Corporation Enhanced solubility pharmaceutical solutions
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
ATE162071T1 (de) * 1993-10-01 1998-01-15 Scherer Corp R P Zusammensetzungen zum verteilen von duftstoffen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9311753A1 *

Also Published As

Publication number Publication date
DE69222031D1 (de) 1997-10-09
US5912011A (en) 1999-06-15
ZA929854B (en) 1994-01-13
CA2103793C (fr) 1999-12-07
AU3278393A (en) 1993-07-19
JP3121080B2 (ja) 2000-12-25
JPH05310566A (ja) 1993-11-22
DE69222031T2 (de) 1998-03-26
WO1993011753A1 (fr) 1993-06-24
CA2103793A1 (fr) 1993-06-20
EP0572627B1 (fr) 1997-09-03
ES2108255T3 (es) 1997-12-16

Similar Documents

Publication Publication Date Title
EP0572627A1 (fr) Systeme de solvant destine a etre enferme dans des capsules.
JP3739391B2 (ja) 強化溶解度の製薬溶液
JP3678745B2 (ja) 高濃度アセトアミノフェン溶液含有ゼラチンカプセル
JP4990474B2 (ja) 軟ゼラチン配合物とともに使用される薬学的組成物の調製方法
US5916590A (en) Soft gelatin pharmaceutical dosage form
US5919481A (en) Fill material for soft gelatin pharmaceutical dosage form
KR880701544A (ko) 이온화 가능한 의약 제제용 용해 시스템
AU2002224317A1 (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
WO1995031979A1 (fr) Solutions d'acides alcanoiques a substitution aryle ou heteroaryle dans des solvants lipophiles, et capsules de gelatine molle contenant de telles solutions
GB2331458A (en) Solvent compositions for gelatin capsules
US5760056A (en) Pharmaceutical formulation
WO2019224832A1 (fr) Procédé de préparation de compositions pharmaceutiques entrainant une réduction du volume de remplissage global pour une utilisation avec des formulations gélatineuses molles
US20230346725A1 (en) Ibuprofen-containing soft gelatin capsules
HK1056326B (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
EP4153149A1 (fr) Capsule de gélatine molle contenant de l'ibuprofène
HK1002751A (en) Artificial hip joint acetabular cup having two shells and its manufacture
MXPA97004847A (en) Filling material for the dosage form of gelatin bla

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930819

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE ES FR GB IT

17Q First examination report despatched

Effective date: 19950524

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE ES FR GB IT

REF Corresponds to:

Ref document number: 69222031

Country of ref document: DE

Date of ref document: 19971009

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2108255

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20101224

Year of fee payment: 19

Ref country code: GB

Payment date: 20101215

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20101215

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20111219

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69222031

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69222031

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20121217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20121217

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120116

Year of fee payment: 20

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20121219